Poxel (POXEL) Q1 2026 earnings summary

Executive summary

• Consolidated net sales of TWYMEEGⓇ in Japan for Q1 2026 reached JPY 2.3 billion (€12.8 million), up 36% year-over-year.

• Poxel generated €1.277 million in revenue for Q1 2026, primarily from royalties on TWYMEEGⓇ sales.

• Sumitomo Pharma expects TWYMEEGⓇ net sales to exceed JPY 10 billion in fiscal year 2026, triggering a milestone payment and increased royalty rate for Poxel.

Financial highlights

• Q1 2026 consolidated revenue was €1.277 million, reflecting 10% royalties from TWYMEEGⓇ net sales in Japan.

• TWYMEEGⓇ net sales in Japan for Sumitomo Pharma reached JPY 9.35 billion (€51 million) for the previous fiscal year, up 40% year-over-year.

• Upon surpassing JPY 10 billion in sales, Poxel will receive a JPY 1 billion (€5.5 million) milestone and a royalty rate increase from 10% to 12%.

Outlook and guidance

• Sumitomo Pharma projects moderate double-digit growth, slightly above 10%, in TWYMEEGⓇ sales for fiscal year 2026.

• Poxel expects to receive 12% royalties on TWYMEEGⓇ net sales in Japan during Sumitomo Pharma's fiscal year 2026.